BOULDER, CO – Enliven Therapeutics, Inc. (NASDAQ:ELVN), a pharmaceutical company with a market capitalization of $1.1 billion, saw its Chief Financial Officer Benjamin Hohl execute a series of stock transactions, according to a recent SEC filing. On December 27 and December 30, Hohl sold a total of 4,250 shares of common stock in Enliven Therapeutics, generating a total of $94,474. The shares were sold at prices ranging from $22.1549 to $22.5061, near the current trading price of $22.50. According to InvestingPro data, the stock has delivered an impressive 61.78% return over the past year.
Prior to these sales, Hohl exercised stock options to acquire 4,250 shares at a price of $2.48 per share. These transactions were conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023. Following these transactions, Hohl no longer holds any shares directly from these particular option exercises. InvestingPro analysis suggests the stock is currently fairly valued, with analysts setting price targets between $33 and $42.
Enliven Therapeutics, based in Boulder, Colorado, is involved in pharmaceutical preparations and continues to be monitored closely by investors for its executive trading activities. The company maintains a strong financial health profile, with more cash than debt on its balance sheet and a robust current ratio of 17.44, indicating excellent liquidity position.
In other recent news, Enliven Therapeutics has been receiving positive attention from various analyst firms. BTIG initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $42.00, focusing on the company’s development of targeted tyrosine kinase inhibitors for cancer treatment. Clear Street also assigned a Buy rating to Enliven Therapeutics with a $36.00 target, citing the company’s potential in the chronic myeloid leukemia treatment market.
Baird increased its price target for Enliven Therapeutics to $40 following promising data from ongoing trials. Jones Trading gave Enliven Therapeutics a Buy rating, predicting worldwide peak sales of approximately $800 million for ELVN-001 by 2036. H.C. Wainwright maintained a Buy rating on Enliven Therapeutics with a steady price target of $37.00, following the presentation of promising Phase 1 results for ELVN-001.
These are all recent developments for Enliven Therapeutics, a company that is advancing two lead tyrosine kinase inhibitors for both solid and liquid cancers. The company’s team includes leading chemists who have been instrumental in the development of four FDA-approved products and have a history of successful acquisitions. Enliven Therapeutics is expected to release key clinical data over the next 12-18 months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
